Lexicon Pharmaceuticals Stock Forecast, Price & News

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lexicon Pharmaceuticals in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Lexicon Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LXRX, but not buy additional shares or sell existing shares.
View analyst ratings for Lexicon Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Lexicon Pharmaceuticals a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Lexicon Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Lexicon Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, July 29th 2021.
View our earnings forecast for Lexicon Pharmaceuticals.

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) issued its quarterly earnings data on Thursday, May, 6th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.17) by $0.02. The biopharmaceutical company had revenue of $0.03 million for the quarter, compared to analyst estimates of $3.35 million. Lexicon Pharmaceuticals had a negative trailing twelve-month return on equity of 13.04% and a negative net margin of 80.64%.
View Lexicon Pharmaceuticals' earnings history.

Lexicon Pharmaceuticals' stock was trading at $2.27 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, LXRX shares have increased by 108.8% and is now trading at $4.74.
View which stocks have been most impacted by COVID-19.

6 analysts have issued 1 year price objectives for Lexicon Pharmaceuticals' stock. Their forecasts range from $6.00 to $13.00. On average, they expect Lexicon Pharmaceuticals' share price to reach $9.40 in the next year. This suggests a possible upside of 98.3% from the stock's current price.
View analysts' price targets for Lexicon Pharmaceuticals or view top-rated stocks among Wall Street analysts.

9 employees have rated Lexicon Pharmaceuticals CEO Lonnel Coats on Glassdoor.com. Lonnel Coats has an approval rating of 100% among Lexicon Pharmaceuticals' employees. This puts Lonnel Coats in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Lexicon Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Exact Sciences (EXAS), Alnylam Pharmaceuticals (ALNY), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Novavax (NVAX), Repligen (RGEN), Neurocrine Biosciences (NBIX) and United Therapeutics (UTHR).
View all of LXRX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Lexicon Pharmaceuticals investors own include Portola Pharmaceuticals (PTLA), Sarepta Therapeutics (SRPT), ACADIA Pharmaceuticals (ACAD), Dynavax Technologies (DVAX), MannKind (MNKD), ImmunoGen (IMGN), Geron (GERN), Micron Technology (MU), TherapeuticsMD (TXMD) and Gilead Sciences (GILD).

Lexicon Pharmaceuticals trades on the NASDAQ under the ticker symbol "LXRX."

Lexicon Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BVF Inc. IL (5.81%), BlackRock Inc. (2.70%), D. E. Shaw & Co. Inc. (2.08%), Pinnacle Associates Ltd. (1.50%), Geode Capital Management LLC (0.75%) and Nomura Holdings Inc. (0.64%). Company insiders that own Lexicon Pharmaceuticals stock include Alexander A Santini, Christopher J Sobecki, James F Tessmer, Lonnel Coats and Sam L Barker.
View institutional ownership trends for Lexicon Pharmaceuticals.

LXRX stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL, Morgan Stanley, Acadian Asset Management LLC, Millennium Management LLC, Renaissance Technologies LLC, Strs Ohio, Price T Rowe Associates Inc. MD, and Cubist Systematic Strategies LLC.
View insider buying and selling activity for Lexicon Pharmaceuticals or view top insider-selling stocks.

LXRX stock was acquired by a variety of institutional investors in the last quarter, including D. E. Shaw & Co. Inc., BlackRock Inc., Nomura Holdings Inc., Boothe Investment Group Inc., Eversept Partners LP, Pinnacle Associates Ltd., Geode Capital Management LLC, and Nuveen Asset Management LLC. Company insiders that have bought Lexicon Pharmaceuticals stock in the last two years include Alexander A Santini, Christopher J Sobecki, James F Tessmer, Lonnel Coats, and Sam L Barker.
View insider buying and selling activity for Lexicon Pharmaceuticals or or view top insider-buying stocks.

Shares of LXRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of LXRX stock can currently be purchased for approximately $4.74.

Lexicon Pharmaceuticals has a market capitalization of $684.40 million and generates $24 million in revenue each year. The biopharmaceutical company earns $-58,570,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis.

Lexicon Pharmaceuticals employs 78 workers across the globe.

The official website for Lexicon Pharmaceuticals is www.lexpharma.com.

Lexicon Pharmaceuticals is headquartered at 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX, 77381.

Lexicon Pharmaceuticals' mailing address is 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX, 77381. The biopharmaceutical company can be reached via phone at 281-863-3000 or via email at [email protected]